Wire · opportunities
Divarasib Improves Survival vs Sotorasib or Adagrasib in KRAS G12C+ NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 October 2026 · Fusion42 review
The phase 3 Krascendo 1 trial demonstrated that divarasib significantly improves progression-free and overall survival compared to first-generation KRAS G12C inhibitors sotorasib and adagrasib in previously treated KRAS G12C-mutated advanced or metastatic non–small cell lung cancer (NSCLC). The trial also showed a favourable safety profile for divarasib with fewer high-grade adverse events.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must update your treatment protocols for KRAS G12C NSCLC fast because divarasib now outperforms sotorasib and adagrasib in survival and safety. This new standard disrupts incumbent first-generation therapies and opens a clearer path for patient outcomes.
◆ Coverage
1 source · 25 Oct 2026
◆ Related on Wire
◆ Topics